Exposures to Eight Factors Contribute to Increasing Trends in IHD, Stroke
These eight factors reversely associated with the age-standardized incidence rates of ischemic heart disease, stroke
AHA: Variation Seen in Rates of SGLT2i Rx for Heart Failure, LVEF >40 Percent
Prescription rates increased from 2021 to 2023, but high variance seen between hospitals in the rate of prescriptions
Heart Failure With Preserved Ejection Fraction Underdiagnosed
Findings seen in patients with severe secondary tricuspid regurgitation of undefined etiology
AHA: Muvalaplin Reduces Lipoprotein(a) Levels in Individuals With Cardiovascular Risk
Reduction in levels seen using an intact lipoprotein(a) assay and apolipoprotein(a)-based assay
President-Elect Trump Names His Picks to Head the CDC and FDA
In addition, the president-elect has chosen his nominee for surgeon general
AHA: Bumetanide Nasal Spray Statistically Bioequivalent to Oral Bumetanide
Nasal spray absorbed more rapidly than oral tablet and has comparable pharmacodynamic effects of diuresis and natriuresis
Considerable Disparities in Life Expectancy Exist Within U.S. Population
Large disparities in life expectancy observed, which grew over time, especially during the first two years of COVID-19
AHA: Initial Catheter Ablation Beneficial for Ventricular Tachycardia
Initial strategy of catheter ablation leads to lower risk for composite primary end point versus antiarrhythmic drug therapy
AHA: Tirzepatide Beneficial for Heart Failure With Preserved EF, Obesity
Lower risk for composite of death from cardiovascular causes or worsening heart failure seen with tirzepatide versus placebo
AHA: Half of U.S. Adults Are Eligible for Treatment With Semaglutide
More than 39 million U.S. adults qualify for indications other than weight management alone
